Asia‐Pacific consensus recommendations on the management of generalized pustular psoriasis
Authors:
- Siew Eng ChoonSCSiew Eng Choon
- Peter Anthony FoleyPFPeter Anthony Foley
- Pravit AsawanondaPAPravit Asawanonda
- Hideki FujitaHFHideki Fujita
- Seong‐Jin JoSJSeong‐Jin Jo
- Yu‐Ling ShiYSYu‐Ling Shi
- Colin ThengCTColin Theng
- Azura Mohd AffandiAAAzura Mohd Affandi
- Chul Hwan BangCBChul Hwan Bang
- Maria Lorna FrezMFMaria Lorna Frez
- Huang Yu HueiHHHuang Yu Huei
- Doanh Le HuuDHDoanh Le Huu
Open Access
- 10 October 2024
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (12) , 1579-1595
Abstract
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogeneous, and potentially life‐threatening disease characterized by primary, sterile, and macroscopically visible pustules with or without systemic symptoms. There are ethnic differences in the genetic mutations associated with GPP that might affect the clinical manifestations and treatment responses. Currently, there is limited evidence from the patient population in the Asia‐Pacific (APAC) region, resulting in a general paucity of information on the effective management of patients with GPP in this region. This modified Delphi panel study aimed to identify current evidence and gain advanced insights to facilitate the development of a regionally tailored APAC consensus on the management of GPP. A systematic literature review (SLR) was conducted to identify published literature and develop consensus statements on (i) definition and clinical course, (ii) diagnosis of GPP, (iii) treatment outcomes, goals, and monitoring measures, and (iv) optimal management strategies and clinical practices. Statements were rated by a panel of dermatologists in two rounds, with the threshold for consensus at ≥80% agreement. Twenty experts from the APAC region reached consensus on 106 statements that were developed based on the SLR and experts' collective expertise. The experts agreed that GPP is a rare, severe, and potentially life‐threatening condition that is distinct from plaque psoriasis. This consensus emphasized the importance of a tailored treatment strategy taking into account the GPP flare severity and each patient's unique clinical circumstances. The experts reached consensus on the severity classification of GPP flares and recommended first‐line and maintenance treatment options for adult GPP, childhood GPP, and GPP in pregnancy. These consensus outcomes have been synthesized into treatment algorithms to guide dermatologists in the APAC region in their clinical decision‐making processes.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 44 references indexed in Scilit:
- International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis CouncilJAMA Dermatology, 2024
- Letter from the editor: Avoiding delays in emergent treatment of generalized pustular psoriasisJournal of the American Academy of Dermatology, 2023
- Generalized pustular psoriasis: A consensus statement from the National Psoriasis FoundationJournal of the American Academy of Dermatology, 2023
- Prevalence and incidence of patients with generalized pustular psoriasis in Denmark—A nationwide registry‐based studyJEADV Clinical Practice, 2023
- Management of adult generalized pustular psoriasis using biologics: A systematic reviewJournal of the American Academy of Dermatology, 2023
- Management of pediatric generalized pustular psoriasis using biologics: An evidence-based reviewJournal of the American Academy of Dermatology, 2022
- Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in JapanJournal of the American Academy of Dermatology, 2022
- Clinical Course and Characteristics of Generalized Pustular PsoriasisAmerican Journal of Clinical Dermatology, 2022
- Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patientsArchives of Dermatological Research, 2015
- Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular PsoriasisThe American Journal of Human Genetics, 2011